Resume

AI governance and assurance for life sciences and healthcare. Albuquerque, New Mexico; remote, U.S. Updated September 2026. Download the PDF or the plain-text version.

Summary

AI governance and assurance specialist for regulated life sciences and healthcare: I write the specification of what trustworthy, auditable AI behavior means and build the evaluation that checks whether a system conforms, including agentic and open-weight systems. Authored Tension OS v2.1, a decision-and-governance methodology with conformance cross-walks to the EU AI Act, ISO/IEC 42001 and NIST AI RMF; designed and built a multi-agent evaluation instrument with pre-committed rubrics, sealed targets, ablation arms, leakage review and provenance export — then commissioned an origin-blind adversarial audit of it, verified six defects in code and maintain the versioned defect register. Regulated-domain judgment from cancer-biology research training and lab operations at MD Anderson, Einstein and Identigene (co-author, ACS Medicinal Chemistry Letters) and eleven years of healthcare-access venture work reviewed by hospital leadership, a payer and bioethics faculty. Executive MBA; bilingual English and Spanish.

Experience

• Jul 2025 – presentFounder, SyncOrch — AI-mediated research-collaboration platform (Albuquerque; remote). Governance, evaluation and assurance work product: the v3 instrument and its audit; Tension OS v2.1; Keel; three public GPTs.
• Aug 2014 – Dec 2025Founder, Patient Support Network — healthcare-access and patient-financing venture (New York, Houston, Philadelphia). Successive models (I Help Today, Celyco, PSN) taken to institutional review; PSN-AI prototype in 2025; converged into SyncOrch in July 2025 and closed in December 2025.
• Aug 2014 – May 2016Executive MBA, Yeshiva University, Sy Syms School of Business.
• Sep 2013 – Jun 2014Laboratory Technician, Albert Einstein College of Medicine — preclinical lung- and pancreatic-cancer therapeutics research (autophagy inhibition). Co-author, ACS Medicinal Chemistry Letters (2014): Discovery of Autophagy Inhibitors with Antiproliferative Activity in Lung and Pancreatic Cancer Cells.
• May 2008 – Oct 2012Founder and Operations Manager, Mizonett Companies (Houston; San Juan) — nonprofit fundraising events (a City of Houston Proclamation for the largest) and residents'-association management under three contracts covering about 800 residential units: budgets, collections, vendors, board governance, local regulatory compliance.
• Nov 2007 – Apr 2008Laboratory Technician, Identigene (Houston) — high-volume parentage DNA analysis in an accredited chain-of-custody workflow; an independent development project on a patented ladder technology.
• Aug 2006 – Jul 2007Graduate Research Assistant, UT MD Anderson Cancer Center / UTHealth Graduate School of Biomedical Sciences — doctoral coursework and three research rotations in cancer biology (a STAT3-inhibitor program whose work contributed to later publications).
• Aug 2000 – May 2006BS, Natural Sciences, University of Puerto Rico, Río Piedras. Summer research at Weill Cornell / Memorial Sloan Kettering (2003) and MD Anderson (2004).

Frameworks and methods

AI governance; AI assurance and audit; Responsible AI; AI risk management; evaluation design and LLM evaluation; red-teaming; agentic AI governance; open-weight model admission; EU AI Act; ISO/IEC 42001; NIST AI RMF; conformance assessment; human oversight; logging and telemetry; decision records; documentation discipline.